Little David G, McDonald Michelle, Bransford Rick, Godfrey Craig B, Amanat Negin
Orthopaedic Research and Biotechnology, University of Sydney, Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Westmead, Australia.
J Bone Miner Res. 2005 Nov;20(11):2044-52. doi: 10.1359/JBMR.050712. Epub 2005 Jul 18.
Bone repair involves both anabolic and catabolic responses. We hypothesized that anabolic treatment with OP-1 (BMP-7) and anti-catabolic treatment with zoledronic acid could be synergistic. In a rat critical defect, this combination therapy produced significant increases in new bone volume and strength.
When used to augment bone healing, osteogenic protein 1 (OP-1/BMP-7) and other BMPs stimulate the anabolic response, inducing osteoblast recruitment, differentiation, and bone production. However, BMPs can also upregulate catabolism by direct stimulation of osteoclasts and indirectly by osteoblasts through RANKL/RANK. We hypothesized that if such osteoclastic upregulation were modulated by zoledronic acid (ZA), the combination of OP-1 and ZA should produce increased new bone over OP-1 alone.
Rats with a surgically induced 6-mm femoral critical size defect were separated into five dosing groups: Carrier, Carrier + ZA, OP-1, OP-1 + ZA, and OP-1 + ZA administered 2 weeks after surgery (2W). Carrier +/- 50 microg OP-1 was placed in the defect, and 0.1 mg/kg ZA or saline was administered subcutaneously. Bone repair was analyzed by radiographs, QCT, mechanical testing, histology, and histomorphometry.
Carrier alone and Carrier ZA groups did not unite by 8 weeks. Radiological union occurred in all OP-1 groups but was tenuous in some animals treated with OP-1 alone. BMC was increased by 45% in the OP-1 ZA group and 96% in the OP-1 ZA 2W group over OP-1 alone (p < 0.01). Callus volume increased over OP-1 alone by 45% and 86% in the OP-1 ZA and OP-1 ZA 2W groups, respectively (p < 0.01). The increased callus volume in the OP-1 ZA 2W group translated to increases in strength of 107% and stiffness of 148% (p < 0.05). BFR was not significantly different between OP-1 groups regardless of ZA treatment.
ZA treatment significantly increased the BMC, volume, and strength of OP-1-mediated callus in a critical size defect in rats at 8 weeks. Thus, modulation of both anabolic and catabolic responses may optimize the amount and mineral content of callus produced, which could be of clinical benefit in obtaining bone union.
骨修复涉及合成代谢和分解代谢反应。我们假设用OP-1(骨形态发生蛋白-7)进行合成代谢治疗和用唑来膦酸进行抗分解代谢治疗可能具有协同作用。在大鼠临界骨缺损模型中,这种联合治疗显著增加了新骨体积和强度。
当用于促进骨愈合时,成骨蛋白1(OP-1/骨形态发生蛋白-7)和其他骨形态发生蛋白刺激合成代谢反应,诱导成骨细胞募集、分化和骨生成。然而,骨形态发生蛋白也可通过直接刺激破骨细胞以及成骨细胞通过核因子κB受体活化因子配体/核因子κB受体活化因子间接上调分解代谢。我们假设,如果这种破骨细胞上调被唑来膦酸(ZA)调节,那么OP-1和ZA联合应用应比单独使用OP-1产生更多的新骨。
将手术造成6毫米股骨临界尺寸缺损的大鼠分为五个给药组:载体组、载体+ZA组、OP-1组、OP-1+ZA组以及术后2周给予OP-1+ZA组(2W)。在缺损处放置含或不含50微克OP-1的载体,并皮下注射0.1毫克/千克ZA或生理盐水。通过X线片、定量CT、力学测试、组织学和组织形态计量学分析骨修复情况。
单独载体组和载体+ZA组在8周时未愈合。所有OP-1组均发生了影像学骨愈合,但单独接受OP-1治疗的部分动物愈合不牢固。与单独使用OP-1相比,OP-1+ZA组的骨矿含量增加了45%,OP-1+ZA 2W组增加了96%(p<0.01)。OP-1+ZA组和OP-1+ZA 2W组的骨痂体积分别比单独使用OP-1组增加了45%和86%(p<0.01)。OP-1+ZA 2W组骨痂体积的增加转化为强度增加107%,刚度增加148%(p<0.05)。无论是否使用ZA治疗,OP-1组之间的骨形成率均无显著差异。
ZA治疗显著增加了大鼠临界尺寸缺损在8周时OP-1介导的骨痂的骨矿含量、体积和强度。因此,调节合成代谢和分解代谢反应可能会优化所产生骨痂的数量和矿物质含量,这在实现骨愈合方面可能具有临床益处。